Protocol Ledger

NCT07325526 · Phase II · RECRUITING

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

Interventional Phase II clinical trial protocol NCT07325526 sponsored by Boehringer Ingelheim in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-27 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07325526
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07325526
Protocol FieldVerified Registry Value
NCT IdentifierNCT07325526
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2026-02-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI